Gilead’s investigational single-tablet regimen of bictegravir and lenacapavir for HIV treatment meets primary endpoint in Phase 3 ARTISTRY-2 trial

Gilead’s investigational single-tablet regimen of bictegravir and lenacapavir for HIV treatment meets primary endpoint in Phase 3 ARTISTRY-2 trial — alphai